Michigan flu cases surge; some kids on ventilators, health officials say

Michigan is experiencing an early, severe influenza season with state officials reporting a 40% increase in hospitalizations year-over-year and 2,110 influenza-related hospitalizations to date, including 306 children ages 4 and under and at least eight pediatric deaths. For the week ending Dec. 27 there were more than 1,400 acute respiratory virus admissions (929 influenza, 378 COVID-19, 128 RSV) and flu accounted for 8% of emergency-department visits; childhood vaccination coverage for 19–35 months has fallen to 68.4% from 75.4% in 2017. Concurrent measles (30 confirmed cases in 2025) and elevated pertussis caseloads, together with the state's move to follow AAP/AAFP immunization schedules after a federal advisory change, create localized operational and demand pressures for hospitals, insurers and pediatric healthcare services.

Analysis

Market-structure: Acute surge in influenza (Michigan hospitalizations +40% YoY; 2,110 season-to-date) disproportionately benefits vaccine makers, distributors and rapid-diagnostics makers (higher volumes, one-off reorder cycles) and hospital operators that can fill beds; payers face near-term claim pressure. Pricing power accrues to distributors (McKesson/MCK) and test-kit suppliers where supply is constrained; hospitals see revenue lift but margin compression from staffing and ICU-capacity costs.

Risk assessment: Key tail risks include a federal/state policy reversal on pediatric vaccine recommendations (demand shock) or a major manufacturing/adverse-event recall; either could compress valuations by >20% in affected names. Time horizons: immediate (days) = testing & short-cycle distributors react; short-term (1–3 months) = vaccine order flows and hospital utilization; long-term (6–18 months) = secular vaccination rates and litigation/regulatory outcomes that re-price vaccine franchises.

Trade implications: Favor long exposure to distributors and diagnostics via size-controlled equity and call-spread option positions (3–6 month horizon) and selective hospital longs vs payer shorts to capture utilization vs claims mismatch. Use clear triggers (weekly flu hospital admissions growth >10% or ACIP/state vaccine mandates) to add exposure; trim if admissions decelerate to <5% week-over-week or ACIP issues negative guidance.

Contrarian angles: Consensus underestimates catch-up vaccination upside for Q2 revenue (historical analog: post-2017–18 season vaccine demand spike) — vaccine makers with supply capacity (SNY, GSK) are under-owned. Conversely, small hospital names may be overbought on headline admissions and vulnerable to reversion if staffing cost trends worsen or if school-level mandates change, creating mean-reversion shorts.

Key Decisions for Investors

• Establish a 2–3% long equity position in McKesson (MCK) for 3–6 months to capture increased vaccine distribution volumes; target +12% and use a stop-loss at -6% or if weekly flu hospital admissions growth drops below +10% YoY for two consecutive weeks.
• Buy a 3-month 30-delta/50-delta call spread on Quidel (QDEL) sized to 1% of portfolio to play near-term demand for rapid flu diagnostics; reduce or close on arrival of two consecutive weeks of negative test-order growth or if implied vol rises >40% above 30-day average.
• Initiate a pair trade: long HCA Healthcare (HCA) 2% / short UnitedHealth Group (UNH) 2% for 1–3 months to capture utilization benefit to hospitals versus immediate claims pain for payers; exit if insurer medical-loss-ratio guidance for the quarter improves >200bps or hospital admission growth falls under +5% weekly.
• Add a 1–2% strategic position in Sanofi (SNY) or GSK (GSK) for 6–12 months to capture upside from catch-up pediatric immunizations; scale up by +50% if ACIP/state-level vaccine recommendations are reaffirmed or Michigan/other large states institute school-entry enforcement within 30–60 days.